ABL1 and acute myeloid leukemia: Additionally, CLAG plus imatinib was well tolerated in these patients and showed promising efficacy as a treatment option for AML patients.153 Other clinical trials in AML have investigated the use of imatinib in combination with approved therapies including LDAC (with insignificant results) and cytarabine and daunorubicin (demonstrating effectiveness) and investigated high-dose imatinib in c-Kit-positive BCR-ABL-negative patients (with no significant improvement).154–156 These studies have demonstrated the effectiveness of using TKIs in combination with 7 + 3 induction therapy in AML.